ChemotherapyFDA-approvedFirst-line
Azacitidine
How it works
Interferes with DNA synthesis, preventing cancer cell growth and division.
Cancer types
Leukemia— MDS
Efficacy
Studies show that azacitidine can induce complete or partial response in approximately 50% of patients with MDS.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Trial for Acute Myeloid Leukemia Treatment in India | Leukemia | preclinical | — | Source → |
| Testing PBSS1113 in Combination With Azacitidine for AML/MDS | Leukemia | phase-1 | — | Source → |
| Testing Azacitidine and Enasidenib for IDH2-Mutant Myelodysplastic Syndrome | Leukemia | phase-2 | — | Source → |
| Combination Therapy for Untreated Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Cladribine and Venetoclax for Monocytic Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Combination Therapy for Acute Myeloid Leukemia: A Phase 2 Clinical Trial | Leukemia | phase-2 | — | Source → |
| Studying Genetic Factors in Acute Myeloid Leukemia | Leukemia | preclinical | — | Source → |
| Testing New Treatment for Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Testing Azacitidine and Chidamide to Prevent Leukemia Relapse | Leukemia | phase-1 | — | Source → |
| Testing Olutasidenib with Azacitidine for Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Comparing Azacitidine with and without Pevonedistat in Acute Myeloid Leukemia | Leukemia | phase-3 | — | Source → |
| Combining Venetoclax and Azacitidine for Acute Myeloid Leukemia Treatment | Leukemia | phase-2 | — | Source → |
| Testing Azacitidine in High-Risk Early Stage Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing a New Treatment Combination for Higher-Risk Myelodysplastic Syndromes | Leukemia | phase-1 | — | Source → |
| Testing Q702 with Azacitidine and Venetoclax for Leukemia | Leukemia | phase-1 | — | Source → |
| New Treatment Combination for Newly Diagnosed Acute Myeloid Leukemia | Leukemia | phase-3 | — | Source → |
| Comparing Treatments for Newly Diagnosed AML Patients | Leukemia | phase-2 | — | Source → |
| New Study Examines Ivosidenib and Azacitidine for AML Patients | Leukemia | phase-3 | — | Source → |
| Testing Azacitidine and Abatacept in T-Cell Lymphoma | Leukemia | phase-1 | — | Source → |
| Axatilimab and Azacitidine Trial for Advanced Blood Cancers | Leukemia | phase-1 | — | Source → |
| Testing Azacitidine and Gemtuzumab Ozogamicin in Older Adults with Untreated Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Azacitidine Helps Some Patients with Blood Cancer Avoid Relapse | Leukemia | phase-2 | 60 (63%) patients were relapse free 6 months after azacitidine initiation. | Source → |
| Long-term remission with combination therapy in AML patient | Leukemia | observational | — | Source → |
| New Treatment Combination Shows Promise for CML Patients | Leukemia | phase-2 | The patients who underwent transplantation had a 50% 3-year probability of survival compared with 18% for nontransplanted patients. | Source → |
| Lab Study Finds New Way to Monitor Azacitidine Treatment in Leukaemia | Leukemia | lab-study | — | Source → |
| Combining PD-1 Inhibitor and Azacitidine for Relapsed Leukemia | Leukemia | phase-2 | The overall response rate after one cycle of the treatment was 75.0% (15/20), and 35.0% (7/20) of the patients achieved complete remission or complete remission with incomplete hematologic recovery after two cycles of the treatment. | Source → |
| Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia | Leukemia | observational | Rates of real-world relapse-free survival and overall survival at 12 months from oral-AZA initiation were 66.9% and 74.5%, respectively. | Source → |
| Azacitidine Therapy in Elderly AML Patients | Leukemia | phase-3 | — | Source → |
| Long-term response to azacitidine in T-cell leukemia relapse | Leukemia | observational | — | Source → |
| Combining Venetoclax and Azacitidine Treats Some Relapsed Acute Myeloid Leukemia Patients | Leukemia | phase-2 | 22.2% of patients in the group achieved complete remission or complete remission with incomplete blood count recovery. | Source → |
| Venetoclax May Be a Good Option for Unfit AML Patients | Leukemia | meta-analysis | Venetoclax plus azacitidine had a hazard ratio of 0.30 compared to enasidenib plus azacitidine, indicating improved survival. | Source → |
| Rare Cancer Treatment Shows Promise with Combination Therapy | Leukemia | lab-study | — | Source → |
| New Cancer Treatment Tested in Phase III Trial | Leukemia | phase-3 | — | Source → |
| CDK7 Inhibitor Shows Promise in Treating Acute Myeloid Leukemia | Leukemia | lab-study | — | Source → |
| Old Patient with Rare Cancer Achieves Remission with New Treatment | Leukemia | observational | — | Source → |
| New Treatments for Older Adults with Acute Myeloid Leukemia | Leukemia | review | — | Source → |
| Chronic Myelomonocytic Leukemia Treatment and Survival Over Three Decades | Leukemia | observational | Median overall survival increased from 10 months to 23 months (p = 0.021). AZA-treated patients had improved survival as compared to CMML patients without AZA therapy (19 vs. 25 months, p = 0.041). | Source → |
| New Treatment Option for Older Adults with Leukemia | Leukemia | phase-3 | Ven+Aza was associated with a gain of 1.65 quality-adjusted life years (QALYs) compared with Aza. | Source → |
| Azacitidine Approved to Treat Rare Blood Cancer in Children | Leukemia | phase-3 | — | Source → |
| New Study Compares Outcomes for Leukemia Patients | Leukemia | phase-3 | — | Source → |
| Combination Therapy Shows Promise for Acute Myeloid Leukemia and Myelodysplastic Syndromes | Leukemia | preclinical | Overall response rates were 30.0% in the AML cohort and 33.3% in the MDS cohort. | Source → |
| Venetoclax and Azacitidine or Decitabine Combination Therapy Risks in Acute Myeloid Leukemia | Leukemia | observational | — | Source → |
| Azacitidine Shows Promise in Treating Elderly Japanese AML Patients | Leukemia | phase-2 | The median survival time of patients who received azacitidine was 9.6 months, compared to 5.3 months for those who received conventional care regimens. | Source → |
| Azacitidine Treatment Boosts T Cell Diversity in AML Patients | Leukemia | lab-study | Patients with elevated pretreatment T cell diversity and those with a boost of TRB richness on day 15 after azacitidine treatment had longer event-free and overall survival. | Source → |
| Combination Therapy Shows Promise for Patients with Certain Type of Leukemia | Leukemia | phase-2 | The composite complete remission rate was 100% in newly diagnosed AML patients, and 58% in relapsed/refractory AML patients. | Source → |
| Combining Azacitidine and Carboplatin May Help Boost Immune Response in Ovarian Cancer | Ovarian Cancer | lab-study | Sequential azacitidine and carboplatin significantly slowed cell growth in 50% of cell lines compared to carboplatin alone. | Source → |
| New Insights into DNA Hypomethylating Therapy for Leukemia | Leukemia | review | — | Source → |
| Combining Cancer Drugs Enhances Leukemia Cell Differentiation | Leukemia | lab-study | Combination treatment enhanced cellular differentiation in TF-1 cells overexpressing IDH2R140Q through increased hemoglobinization and increased hemoglobin γ RNA expression compared with the effects of single agents. | Source → |
| New Blood Test May Help Predict Outcomes for Leukemia Patients | Leukemia | observational | The 1-year overall survival rate was 35.6% for patients with a high Fibrinogen-Albumin Ratio Index and 77.5% for those with a low FARI. | Source → |
| New Response Criteria Considered for Acute Myeloid Leukemia Treatment | Leukemia | phase-2 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.